Stock Track | Galapagos NV (GLPG) Stock Soars 5.11% on Promising Pipeline and Earnings Outlook

Stock Track

02-13

Galapagos NV (GLPG) stock surged 5.11% on Wednesday during intraday trading, outperforming the broader market. The biopharmaceutical company's strong pipeline, particularly its cell therapy platform targeting cancer, and expectations of better earnings appear to be driving the stock's upward momentum.

According to the news report, Galapagos NV is focused on developing innovative medicines in oncology and immunology, with promising CAR-T candidates like GLPG5101 and GLPG5201 targeting lymphoma and leukemia. The company's decentralized CAR-T manufacturing platform enables fast and personalized treatments, potentially addressing unmet medical needs.

Furthermore, Galapagos NV reported positive financial results for the third quarter of 2024, with an operating profit of €66.0 million, up from €23.0 million in the previous year. The company also had €3.3 billion in cash and investments, positioning it well for future growth and expansion.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1176032432"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1176032432\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1176032432?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-13 04:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1176032432","market":"us","top_or_hot":-1,"title":"Stock Track | Galapagos NV (GLPG) Stock Soars 5.11% on Promising Pipeline and Earnings Outlook","media":"Stock Track","content":"<p>Galapagos NV (GLPG) stock surged 5.11% on Wednesday during intraday trading, outperforming the broader market. The biopharmaceutical company's strong pipeline, particularly its cell therapy platform targeting cancer, and expectations of better earnings appear to be driving the stock's upward momentum.</p>\n\n<p>According to the news report, Galapagos NV is focused on developing innovative medicines in oncology and immunology, with promising CAR-T candidates like GLPG5101 and GLPG5201 targeting lymphoma and leukemia. The company's decentralized CAR-T manufacturing platform enables fast and personalized treatments, potentially addressing unmet medical needs.</p>\n\n<p>Furthermore, Galapagos NV reported positive financial results for the third quarter of 2024, with an operating profit of €66.0 million, up from €23.0 million in the previous year. The company also had €3.3 billion in cash and investments, positioning it well for future growth and expansion.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Galapagos NV (GLPG) Stock Soars 5.11% on Promising Pipeline and Earnings Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Galapagos NV (GLPG) Stock Soars 5.11% on Promising Pipeline and Earnings Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-13 04:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Galapagos NV (GLPG) stock surged 5.11% on Wednesday during intraday trading, outperforming the broader market. The biopharmaceutical company's strong pipeline, particularly its cell therapy platform targeting cancer, and expectations of better earnings appear to be driving the stock's upward momentum.</p>\n\n<p>According to the news report, Galapagos NV is focused on developing innovative medicines in oncology and immunology, with promising CAR-T candidates like GLPG5101 and GLPG5201 targeting lymphoma and leukemia. The company's decentralized CAR-T manufacturing platform enables fast and personalized treatments, potentially addressing unmet medical needs.</p>\n\n<p>Furthermore, Galapagos NV reported positive financial results for the third quarter of 2024, with an operating profit of €66.0 million, up from €23.0 million in the previous year. The company also had €3.3 billion in cash and investments, positioning it well for future growth and expansion.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GLPG","symbol_name":"Galapagos NV","start_time":0,"source_url":"","article_id":"1176032432","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1176032432","pubTimestamp":1739392476,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Galapagos NV  stock surged 5.11% on Wednesday during intraday trading, outperforming the broader market. The biopharmaceutical company's strong pipeline, particularly its cell therapy platform targeting cancer, and expectations of better earnings appear to be driving the stock's upward momentum.According to the news report, Galapagos NV is focused on developing innovative medicines in oncology and immunology, with promising CAR-T candidates like GLPG5101 and GLPG5201 targeting lymphoma and leuke","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GLPG":"Galapagos NV"},"translate_title":"股票追踪Galapagos NV(GLPG)股价因管道和盈利前景看好而飙升5.11%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GLPG":1},"content_text":"Galapagos NV (GLPG) stock surged 5.11% on Wednesday during intraday trading, outperforming the broader market. The biopharmaceutical company's strong pipeline, particularly its cell therapy platform targeting cancer, and expectations of better earnings appear to be driving the stock's upward momentum.\nAccording to the news report, Galapagos NV is focused on developing innovative medicines in oncology and immunology, with promising CAR-T candidates like GLPG5101 and GLPG5201 targeting lymphoma and leukemia. The company's decentralized CAR-T manufacturing platform enables fast and personalized treatments, potentially addressing unmet medical needs.\nFurthermore, Galapagos NV reported positive financial results for the third quarter of 2024, with an operating profit of €66.0 million, up from €23.0 million in the previous year. The company also had €3.3 billion in cash and investments, positioning it well for future growth and expansion.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}